Ann: Trading Halt, page-86

I think any interested party won't need the results to be as amazing as PMS. Signs of efficacy comparable to Trofinetide would be very enticing as that ended up on market with the biggest concern being the GI tolerance issues that don't seem to arise with 2591. That would be plenty I believe to spike interest to a high level as the idea of a single compound to treat multiple diseases is in play. A big pharma with deep pockets could easily look at exploring adjusted dosing regimens to improve on the efficacy in other conditions so I don't think the bar has to be as high as what's been set by 2591s first results. I think the biggest negotiation point for any buyer right now is that they're only at Phase 2 with small study sizes. That needs to be considered to keep valuations in perspective.